(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.57%) $79.45
(1.24%) $1.956
(0.73%) $2 327.90
(0.16%) $26.79
(1.19%) $966.30
(0.03%) $0.933
(0.00%) $11.03
(-0.06%) $0.798
(0.27%) $93.51
Live Chart Being Loaded With Signals
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis...
Stats | |
---|---|
本日の出来高 | 100 125 |
平均出来高 | 33 159.00 |
時価総額 | 27 549.00 |
EPS | €0 ( 2024-04-19 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 0 |
ATR14 | €0.00400 (3.17%) |
Pharnext SA 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Pharnext SA 財務諸表
Annual | 2022 |
収益: | €558.00 |
総利益: | €2.26M (404 643.19 %) |
EPS: | €-8.32 |
FY | 2022 |
収益: | €558.00 |
総利益: | €2.26M (404 643.19 %) |
EPS: | €-8.32 |
FY | 2021 |
収益: | €84 785.00 |
総利益: | €0.00 (0.00 %) |
EPS: | €-5 033.08 |
FY | 2020 |
収益: | €39 830.00 |
総利益: | €-284 720 (-714.84 %) |
EPS: | €-5 920.66 |
Financial Reports:
No articles found.
Pharnext SA
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。